Arimoclomol Terminated Phase 3 Trials for Inclusion Body Myositis (IBM) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04049097Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial